Biology of Blood and Marrow Transplantation
Volume 10, Issue 3 , Pages 171-177 , March 2004

Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation

  • Elena G Chiorean

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • Division of Medical Hematology, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Todd E DeFor

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Daniel J Weisdorf

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • Division of Medical Hematology, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Bruce R Blazar

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • Division of Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Philip B McGlave

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • Division of Medical Hematology, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Linda J Burns

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • Division of Medical Hematology, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Charlotte Brown

      Affiliations

    • Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Jeffrey S Miller

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • Division of Medical Hematology, University of Minnesota, Minneapolis, Minnesota, USA
    • Corresponding Author InformationCorrespondence and reprint requests: Jeffrey S. Miller, MD, Department of Medicine, University of Minnesota Cancer Center, MMC 806, Division of Hematology, Oncology and Transplantation, Harvard St. at E. River Rd., Minneapolis, MN 55455 USA

Received 25 April 2003 ,Accepted 14 October 2003.

References 

  1. Kolb HJ, Schattenberg A, Goldman JM, et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  2. Collins RH, Shpilberg O, Drobyski WR, et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444
  3. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras (a critical role for host antigen-presenting cells). Blood. 2002;100:1903–1909
  4. Baurmann H, Nagel S, Binder T, Neubauer A, Siegert W, Huhn D. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood. 1998;92:3582–3590
  5. Dazzi F, Szydlo RM, Cross NC, et al.  Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000;96:2712–2716
  6. Schattenberg A, Schaap N, Van De Wiel-Van Kemenade E, et al.  In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. Leuk Lymphoma. 1999;32:317–325
  7. Schichman SA, Suess P, Vertino AM, Gray PS. Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment. Bone Marrow Transplant. 2002;29:243–248
  8. Thomas ED, Storb R, Clift RA, et al.  Bone marrow transplantation. N Engl J Med. 1975;292:895–902
  9. Shulman HM, Sullivan KM, Weiden PL, et al.  Chronic graft-versus-host syndrome in man (A long-term clinico-pathologic study in 20 Seattle patients). Am J Med. 1980;69:204–217
  10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  11. Lin DY. Non-parametric inference for cumulative incidence functions in competing risk studies. Stat Med. 1997;16:901–910
  12. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220
  13. Keil F, Haas O, Fritsch G, et al.  Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation (lack of residual donor hematopoiesis predicts aplasia). Blood. 1997;89:3113–3117
  14. Dazzi F, Goldman J. Donor lymphocyte infusions. Curr Opin Hematol. 1999;6:394–399
  15. Mrsic M, Horowitz MM, Atkinson K, et al.  Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 1992;9:269–275
  16. Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydlo R, Zwaan FE. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol. 1991;79:567–574
  17. Bosi A, Laszlo D, Labopin M, et al.  Second allogeneic bone marrow transplantation in acute leukemia (results of a survey by the European Cooperative Group for Blood and Marrow Transplantation). J Clin Oncol. 2001;19:3675–3684
  18. Dazzi F, Goldman J. Donor lymphocyte infusions. Curr Opin Hematol. 1999;6:394–399
  19. Carlens S, Remberger M, Aschan J, Ringden O. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant. 2001;7:31–38
  20. Verdonck LF, Petersen EJ, Lokhorst HM, et al.  Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation (impact of infused and residual donor T cells). Bone Marrow Transplant. 1998;22:1057–1063
  21. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.  Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation (predictive factors for response and long-term outcome). J Clin Oncol. 2000;18:3031–3037
  22. Kantarjian HM, O’Brien S, Cortes JE, et al.  Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002;100:1590–1595
  23. Olavarria E, Craddock C, Dazzi SF, et al.  Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood. 2002;99:3861–3862

PII: S1083-8791(03)00395-1

doi: 10.1016/j.bbmt.2003.10.004

Biology of Blood and Marrow Transplantation
Volume 10, Issue 3 , Pages 171-177 , March 2004

Article Tools

* Image Usage & Resolution